PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2025

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS mutant patients, who are not eligible to EGFR inhibitors, have a lower number of available treatment options and usually receive fewer lines of treatment compared with patients with RAS wild-type disease. The CRC competitive landscape is going to experience a substantial change, following the approval of pipeline agents exploiting novel mechanisms of actions, especially immunotherapy. Some pipeline drug developers have invested heavily in the identification of potential predictive biomarkers; therefore, these novel agents are expected to induce further patient stratification and to add complexity to the CRC treatment algorithm, which will be also reshaped by the discovery of the predictive value of tumor sidedness.

Scope

Overview of CRC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized CRC therapeutics market revenue, cost of therapy, and treatment usage pattern data in 8 patient segments, forecast from 2015 to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CRC therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global CRC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The CRC market is characterized by a number of unmet needs in the current treatments. What are the main unmet needs in this market? Will the pipeline drugs under development fulfil these unmet needs?

The CRC market leader Avastin will experience competition from bevacizumab biosimilars, after its patent expiration in 2018. What will be the impact of bevacizumab biosimilars on the CRC market?

Nine late-stage pipeline agents are going to enter the CRC market from 2017 onwards. Will the late-stage drugs make a significant impact on the CRC market? Which of these drugs will have the highest peak sales, and why?

Companies mentioned

AB Science

Amgen

Array BioPharma

AstraZeneca

Bayer

Biocad

Boehringer Ingelheim

Bristol-Myers Squibb

BTG International

Daiichi-Sankyo

Cleveland Biolabs

Eli Lilly

GlaxoSmithKline

Gradalis

Hutchinson Medi Pharma

Immunomedics ...

AB Science

Amgen

Array BioPharma

AstraZeneca

Bayer

Biocad

Boehringer Ingelheim

Bristol-Myers Squibb

BTG International

Daiichi-Sankyo

Cleveland Biolabs

Eli Lilly

GlaxoSmithKline

Gradalis

Hutchinson Medi Pharma

Immunomedics

Immunovative Therapies

Jiangsu Hengrui

Merck KGaA

Merck & Co.

Merrimack

Mologen

Novartis

PsiOxus therapeutics

Roche/Genentech

Sanofi

Sorrento

Sirtex

Sumitomo Dainippon Pharma

Suzhou Zelgen

Symphogen

Taiho Pharmaceuticals

Takeda

Tracon Pharmaceuticals

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.1.3 Biomarkers/ Targets of interest

3.2 Clinical Staging

3.3 Symptoms

3.4 Prognosis

3.5 Quality of Life

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.3.1 8MM Incidence Trends

4.3.2 8MM, Trends in Five-Year Relative Survival

4.4 Forecast Methodology

4.4.1 Sources Used Tables

4.4.2 Forecast Assumptions and Methods

4.4.3 Sources Not Used

4.5 Epidemiological Forecast for CRC (2015–2025)

4.5.1 Diagnosed Incident Cases of CRC

4.5.2 Age-Specific Diagnosed Incident Cases of CRC

4.5.3 Sex-Specific Diagnosed Incident Cases of CRC

4.5.4 Age-Standardized Diagnosed Incidence of CRC

4.5.5 Diagnosed Incident Cases of CRC by Stage at Diagnosis

4.5.6 Type of Genetic Mutation among Diagnosed Incident Cases of CRC

4.5.7 Five-Year Diagnosed Prevalent Cases of CRC

4.6 Discussion

4.6.1 Epidemiological Forecast Insight

4.6.2 Limitations of the Analysis

4.6.3 Strengths of the Analysis

5 Disease Management

5.1 Diagnosis and Treatment Overview

5.1.1 Screening and Diagnosis

5.1.2 Treatment Guidelines and Leading Prescribed Drugs

5.1.3 Clinical Practice

5.2 US

5.2.1 Screening and Diagnosis

5.2.2 Clinical Practice

5.3 France

5.3.1 Screening and Diagnosis

5.3.2 Clinical Practice

5.4 Germany

5.4.1 Screening and Diagnosis

5.4.2 Clinical Practice

5.5 Italy

5.5.1 Screening and Diagnosis

5.5.2 Clinical Practice

5.6 Spain

5.6.1 Screening and Diagnosis

5.6.2 Clinical Practice

5.7 UK

5.7.1 Screening and Diagnosis

5.7.2 Clinical Practice

5.8 Japan

5.8.1 Screening and Diagnosis

5.8.2 Clinical Practice

5.9 China

5.9.1 Screening and Diagnosis

5.9.2 Clinical Practice

6 Competitive Assessment

6.1 Overview

6.2 Anti-angiogenesis drugs

6.2.1 Avastin (Bevacizumab)

6.2.2 Zaltrap (Ziv-Aflibercept)

6.2.3 Cyramza (Ramucirumab)

6.3 EGFR Targeted-therapies

6.3.1 Erbitux (Cetuximab)

6.3.2 Vectibix (Panitumumab)

6.4 Kinase Inhibitors

6.4.1 Stivarga (Regorafenib)

6.5 Chemotherapy

6.5.1 Lonsurf (Trifluridine + Tipiracil)

6.5.2 TS-1 (Tegafur + Gimeracil + Oteracil)

7 Unmet Need and Opportunity

7.1 Overview

7.2 Understanding and Overcoming Mechanisms of Resistance to Angionesis and EGFR Inhibitors

7.2.1 Unmet Need

7.2.2 Gap Analysis

7.2.3 Opportunity

7.3 Targeted Treatments for BRAF Mutation-Positive Patients

7.3.1 Unmet Need

7.3.2 Gap Analysis

7.3.3 Opportunity

7.4 Extending the Use of Immunotherapies to the MSS Population

7.4.1 Unmet Need

7.4.2 Gap Analysis

7.4.3 Opportunity

7.5 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease

7.5.1 Unmet Need

7.5.2 Gap Analysis

7.5.3 Opportunity

7.6 Identification of Positive Predictive Biomarkers

7.6.1 Unmet Need

7.6.2 Gap Analysis

7.6.3 Opportunity

7.7 Additional and More Effective Later-Line Therapies for Chemotherapy-Resistant Patients

7.7.1 Unmet Need

7.7.2 Gap Analysis

7.7.3 Opportunity

8 Pipeline Assessment

8.1 Overview

8.2 Promising Drugs in Clinical Development

8.3 Immunotherapies

8.3.1 Lefitolimod (MGN-1703)

8.3.2 Keytruda (Pembrolizumab)

8.3.3 Tecentriq (Atezolizumab)

8.4 Molecular-Targeted Agents

8.4.1 Encorafenib (LGX-818) + Binimetinib (MEK-162)

8.4.2 Napabucasin (BBI-608)

8.4.3 Vargatef (Nintedanib)

8.4.4 Masitinib (AB-1010)

8.4.5 Fruquintinib (HMPL-013)

8.4.6 Famitinib (SHR-1020)

8.4.7 Donafenib (CM-4307)

8.5 Promising Approaches in Early Stage Development

8.5.1 Strategies to Overcome VEGF-Resistance

8.5.2 Strategies for BRAF Mutation-Positive Disease

8.5.3 Strategies for RAS-Mutation Positive Disease

8.5.4 Strategies to Overcome EGFR-Acquired Resistance

8.5.5 Immune Checkpoint Inhibitor Combinations

8.5.6 Other Strategies

8.5.7 Liver-Directed Therapies

8.6 Biosimilars

8.6.1 Bevacizumab Biosimilars

8.6.2 Cetuximab Biosimilars

9 Current and Future Players

9.1 Overview

9.2 Trends in Corporate Strategy

9.3 Company Profiles

9.3.1 Amgen

9.3.2 Bayer

9.3.3 Eli Lilly and Company

9.3.4 Merck KGaA

9.3.5 Merck & Co.

9.3.6 Roche/Genentech

9.3.7 Taiho Pharmaceutical

10 Market Outlook

10.1 Global Markets

10.1.1 Forecast

10.1.2 Drivers and Barriers – Global Issues

10.2 United States

10.2.1 Forecast

10.2.2 Key Events

10.2.3 Drivers and Barriers

10.3 5 EU

10.3.1 Forecast

10.3.2 Key Events

10.3.3 Drivers and Barriers

10.4 Japan

10.4.1 Forecast

10.4.2 Key Events

10.4.3 Drivers and Barriers

10.5 China

10.5.1 Forecast

10.5.2 Key Events

10.5.3 Drivers and Barriers

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.4 Forecasting Methodology

11.4.1 Diagnosed CRC Patients

11.4.2 Percent Drug-Treated Patients

11.4.3 Drugs Included in Each Therapeutic Class

11.4.4 Launch and Patent Expiry Dates

11.4.5 General Pricing Assumptions

11.4.6 Individual Drug Assumptions

11.4.7 Generic Erosion

11.4.8 Pricing of Pipeline Agents

11.5 Primary Research – KOLs Interviewed for this Report

11.6 Primary Research – Prescriber Survey

11.7 About the Authors

11.7.1 Analyst

11.7.2 Reviewers

11.7.3 Therapy Area Director

11.7.4 Epidemiologist

11.7.5 Reviewers

11.7.6 Global Head of Healthcare

11.8 About GlobalData

11.9 Disclaimer

List of tables

List of Tables

Table 1: Stage Definitions for Colorectal Cancer

Table 2: Symptoms of CRC

Table 3: Prognosis for Colon and Rectal Cancer

Table 4 ...

List of Tables

Table 1: Stage Definitions for Colorectal Cancer

Table 2: Symptoms of CRC

Table 3: Prognosis for Colon and Rectal Cancer

Table 4: Risk Factors and Comorbidities For CRC

Table 5: 8MM, Five-Year Relative Survival (%)

Table 6: 8MM, Sources Used to Forecast the Diagnosed Incidence of CRC

Table 7: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of CRC

Table 8: 8MM, Sources of CRC Cancer Stage at Diagnosis

Table 9: 8MM, Sources of Genetic Mutations

Table 10: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025

Table 11: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Row (%), 2015

Table 12: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, Row (%), 2015

Table 13: 8MM, Diagnosed Incident Cases of CRC by Cancer Stage at Diagnosis (N), Ages ≥18 Years, Row (%), 2015

Table 14: 8MM, Diagnosed Incident Cases of CRC by Type of Genetic Mutation (N), Both Sexes, Ages ≥18 Years, 2015

Table 15: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025

Table 16: Treatment Guidelines for CRC

Table 17: Most Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage Colon and Rectal Cancer in the 8MM, 2016

Table 18: Most Prescribed Targeted Therapies for mCRC, by Segment in the 8MM, 2016

Table 19: Country Profile – US

Table 20: Country Profile – France

Table 21: Country Profile – Germany

Table 22: Country Profile – Italy

Table 23: Country Profile – Spain

Table 24: Country Profile – UK

Table 25: Country Profile – Japan

Table 26: Country Profile – China

Table 27: Leading Treatments for CRC, 2016

Table 28: Product Profile — Avastin

Table 29: Summary of the Results from the AVF2107 Trial of Avastin Plus IFL

Table 30: Summary of the Results from the CALGB 80405 and FIRE-3 Trials of Avastin/Erbitux plus Chemotherapy

Table 31: Summary of the Results of the ML18147 Study

Table 32: Summary of the Results from the E3200 Trial of Avastin Plus FOLFOX

Table 33: Summary of AEs from the AVF21070 trial of Avastin

Table 34: Avastin SWOT Analysis, 2016

Table 35: Product Profile – Zaltrap

Table 36: Summary of the Results from the VELOUR Study

Table 37: Summary of Frequent Grade 3 and 4 AEs from the VELOUR trial of Zaltrap

Table 38: Zaltrap SWOT Analysis, 2016

Table 39: Product Profile – Cyramza

Table 40: Summary of the Phase III RAISE Trial of Cyramza

Table 41: Summary of Frequent Grade 3 and 4 AEs in a Phase III Trial for Cyramza

Table 42: Cyramza SWOT Analysis, 2016

Table 43: Product Profile — Erbitux

Table 44: Summary of the Result of the CRYSTAL Study

Table 45: Summary of the Results of the CRYSTAL Study – BRAF Mutation

Table 46: Retrospective Analysis of CRYSTAL and FIRE-3 Studies of Erbitux

Table 47: Summary of Frequent AEs from the CRYSTAL Trial of Erbitux

Table 48: Erbitux SWOT Analysis, 2016

Table 49: Product Profile – Vectibix

Table 50: Summary of the Results from the PRIME Trial of Vectibix

Table 51: Summary of the Results from the PEAK Study of Vectibix

Table 52: Summary of the Results from the Phase III Study of Vectibix as Monotherapy

Table 53: Summary of the Results from the ASPECCT Study of Vectibix

Table 54: Incidence of Grade 3–4 AEs of the PRIME Trial of Vectibix

Table 55: Vectibix SWOT Analysis, 2016

Table 56: Product Profile – Stivarga

Table 57: Summary of the Results from the CORRECT Study of Stivarga

Table 58: Summary of Frequent Grade 3 and 4 AEs from the CORRECT Trial of Stivarga

Table 59: Stivarga SWOT Analysis, 2016

Table 60: Product Profile – Lonsurf

Table 61: Summary of the Phase III RECOURSE Trial of Lonsurf

Table 62: Summary of the AEs in the Phase III Trial of Lonsurf

Table 63: Lonsurf SWOT Analysis, 2016

Table 64: Product Profile – TS-1

Table 65: Summary of a Phase III trial of TS-1

Table 66: Summary of Most Common AEs in a Phase III Trial of TS-1

Table 67: TS-1 SWOT Analysis, 2016

Table 68: Unmet Needs and Opportunities in CRC

Table 69: Product Profile – Lefitolimod

Table 70: Summary of the IMPACT Trial of Lefitolimod

Table 71: Summary of the Most Common AEs Reported in the IMPACT Trial of Lefitolimod

Table 72: Lefitolimod SWOT Analysis, 2016

Table 73: Product Profile – Keytruda

Table 74 Summary of the Results of the Phase II Trial of Keytruda

Table 75: Summary of Frequent AEs in the Phase II Trial of Keytruda

Table 76: Keytruda SWOT analysis, 2016

Table 77: Product Profile – Tecentriq

Table 78: Summary of the Phase Ib Trial of Tecentriq

Table 79: Summary of Frequent AEs in the Phase Ib Trial of Tecentriq

Table 80: Tecentriq SWOT analysis, 2016

Table 81: Product Profile – Encorafenib +Binimetinib

Table 82: Summary of the Results from the Phase II Trial of Encorafenib

Table 83: Summary of Frequent AEs in the Phase II Trial of Encorafenib

Table 84: Encorafenib + Binimetinib – SWOT Table, 2016

Table 85: Product Profile – Napabucasin

Table 86: Summary of the Result from the Phase Ib Trial of Napabucasin

Table 87: Summary of the Result from the Phase II Trial Investigating Napabucasin + Vectibix

Table 88: Napabucasin, SWOT Analysis, 2016

Table 89: Product Profile – Vargatef

Table 90: Summary of the Results of the Phase III LUME Colon-1 Trial of Vargatef

Table 91: Vargatef SWOT Analysis, 2016

Table 92: Product Profile – Masitinib

Table 93: Summary of the Results of the Phase II Trial of Masitinib

Table 94: Masitinib SWOT Analysis, 2016

Table 95: Product Profile – Fruquintinib

Table 96: Summary of the Results of the Phase II Trial of Fruquintinib

Table 97: Summary of Frequent AEs in the Phase II Trial of Fruquintinib

Table 98: Fruquintinib SWOT Analysis, 2016

Table 99: Product Profile – Famitinib

Table 100: Summary of the Results of the Phase II Trial of Famitinib

Table 101: Summary of Frequent AEs in a Phase II trial of Famitinib

Table 102: Famitinib SWOT Analysis, 2016

Table 103: Product Profile – Donafenib

Table 104:Donafenib SWOT Analysis, 2016

Table 105: Promising Strategies to Overcome VEGF Resistance

Table 106: Early-stage Strategies for BRAF Mutation-Positive CRC

Table 107: Early-Stage Strategies for KRAS Mutation-Positive CRC

Table 108: Early-Stage Strategies for EGFR Acquired Resistance

Table 109: Anti-PD1 and Anti-PDL1 Drugs in Early-Stage Development for CRC

Table 110: CAR-T Cell Therapies Under Development

Table 111: Vaccines in Development for CRC

Table 112: Radioembolization Techniques Evaluated for the Treatment of CRC Liver Metastasis

Table 113: List of Bevacizumab Biosimilars in Phase III Development

Table 114: Key Companies in the CRC Market in the 8MM, 2015–2025

Table 115: Amgen’s CRC Portfolio Assessment, 2016

Table 116: Bayer’s CRC Portfolio Assessment, 2016

Table 117: Eli Lilly’s CRC Portfolio Assessment, 2016

Table 118: Merck KGaA’s CRC Portfolio Assessment, 2016

Table 119: Merck & Co.’s CRC Portfolio Assessment, 2016

Table 120: Roche’s CRC Portfolio Assessment, 2016

Table 121: Taiho’s CRC Portfolio Assessment, 2016

Table 122: CRC Market Drivers and Barriers, 2016

Table 123: Key Events Impacting Sales for CRC in the US, 2015–2025

Table 124: US CRC Market Drivers and Barriers, 2016

Table 125: Key Events Impacting Sales for CRC in the 5EU, 2015–2025

Table 126: 5EU CRC Market Drivers and Barriers, 2016

Table 127: Key Events Impacting Sales for CRC in Japan, 2015–2025

Table 128: Japan CRC Market – Drivers and Barriers, 2016

Table 129: Key Events Impacting Sales for CRC in China, 2015–2025

Table 130: China CRC Market – Drivers and Barriers, 2016

Table 131: Key Historical and Projected Launch Dates for Colorectal Cancer

Table 132: Key Historical and Projected Patent Expiry Dates for Colorectal Cancer

Table 133 Average Body Weight and Surface Area Across the 8MM

Table 134: Treatment Duration in Colorectal Cancer

Table 135: Average Cost of Therapy of Avastin in the 8MM

Table 136: Average Cost per Cycle of Chemotherapy Regimens in the 8MM

Table 137: Average Cost of Therapy of Cyramza in the 8MM (excluding urban China)

Table 138: Average Cost of Therapy of Erbitux in the 8MM

Table 139: Average Cost of Therapy of Lonsurf in the 8MM

Table 140: Average Cost of Therapy of Stivarga in the 8MM

Table 141: Average Cost of Therapy of Vectibix in the 8MM

Table 142: Average Cost of Therapy of Zaltrap in the US and 5EU

Table 143: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

List of Figures

Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages ≥15 Years, 1998–2007

Figure 2: 8MM ...

List of Figures

Figure 1: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Men, Ages ≥15 Years, 1998–2007

Figure 2: 8MM, Age-Adjusted Incidence Rate for CRC (Cases per 100,000 Population), Women, Ages ≥15 Years, 1998–2007

Figure 3: 8MM, Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025

Figure 4: 8MM, Age-Specific Diagnosed Incident Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015

Figure 5: 8MM, Sex-Specific Diagnosed Incident Cases of CRC (N), Ages ≥18 Years, 2015

Figure 6: 8MM, Age-Standardized Incidence of CRC (Cases per 100,000 Population), Ages ≥18 Years, by Sex, 2015.

Figure 7: 8MM, Five-Year Diagnosed Prevalent Cases of CRC (N), Both Sexes, Ages ≥18 Years, 2015–2025

Figure 8: Treatment Flowchart for Regional or Locoregional CRC

Figure 9: Treatment Flowchart for mCRC

Figure 10: The Zurich Treatment Algorithm

Figure 11: Avastin’s Development in CRC

Figure 12: Cyramza’s Development in CRC

Figure 13: Erbitux’s Development in CRC

Figure 14: Vectibix’s Development in CRC

Figure 15: Stivarga’s Development in CRC

Figure 16: Lonsurf’s Development in CRC

Figure 17: TS-1’s Development in CRC

Figure 18: CRC – Phase III Pipeline, 2016

Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in CRC, 2015-2025

Figure 20: Lefitolimod’s Clinical Development in CRC

Figure 21: Clinical and Commercial Positioning of Lefitolimod

Figure 22: Keytruda’s Clinical Development in CRC

Figure 23: Clinical and Commercial Positioning of Keytruda

Figure 24: Tecentriq’s Clinical Development in CRC

Figure 25: Clinical and Commercial Positioning of Tecentriq

Figure 26: Encorafenib’s Clinical Development in CRC

Figure 27: Clinical and Commercial Positioning of Encorafenib + Binimetinib

Figure 28: Napabucasin’s Clinical Development in CRC

Figure 29: Clinical and Commercial Positioning of Napabucasin

Figure 30: Vargatef’s Clinical Development in CRC

Figure 31: Clinical and Commercial Positioning of Vargatef

Figure 32:Masitinib’s Clinical Development in CRC

Figure 33: Clinical and Commercial Positioning of Masitinib

Figure 34: Fruquintinib’s Clinical Development in CRC

Figure 35: Clinical and Commercial Positioning of Fruquintinib

Figure 36: Famitinib’s Clinical Development in CRC

Figure 37: Clinical and Commercial Positioning of Famitinib

Figure 38: Donafenib’s Clinical Development in CRC

Figure 39: Clinical and Commercial Positioning of Donafenib

Figure 40: Clinical Development of Bevacizumab Biosimilars

Figure 41: Global Sales of Branded Products for CRC by Company, 2015–2025

Figure 42: Company Portfolio Gap Analysis in CRC, 2015–2025

Figure 43: Amgen SWOT Analysis in CRC, 2016

Figure 44: Bayer SWOT Analysis in CRC, 2016

Figure 45: Eli Lilly SWOT Analysis in CRC, 2016

Figure 46: Merck KGaA SWOT Analysis in CRC, 2016

Figure 47: Merck & Co. SWOT Analysis in CRC, 2016

Figure 48: Roche SWOT Analysis in CRC, 2016

Figure 49: Taiho SWOT Analysis in CRC, 2016

Figure 50: Global Sales for CRC by Region, 2015–2025

Figure 51: Global Sales for CRC by Drug Class, 2015–2025

Figure 52: Sales for CRC in the US, by Drug Class, 2015–2025

Figure 53: Sales for CRC in the 5EU, by Drug Class, 2015–2025

Figure 54: Sales for CRC in Japan, by Drug Class, 2015–2025

Figure 55: Sales for CRC in China by Drug Class, 2015–2025

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports